NurExone Biologic Inc.: Unveiling vision-restoring strategy at ARVO 2025, showcasing promising preclinical data
In a groundbreaking development, NurExone Biologic Inc., a preclinical-stage biotech company specializing in exosome-based therapies for central nervous system injuries, unveiled promising preclinical data on optic nerve regeneration. This data was presented today at the prestigious Association for Research in Vision and Ophthalmology (ARVO) conference in Salt Lake City, Utah, the epicenter of vision science research.
The Lowdown on ExoPTEN
Professor Ygal Rotenstreich, director of the Retinal Research Lab at Sheba Medical Center and lead researcher, shared the findings that exosome-based therapy, dubbed ExoPTEN, restored retinal activity and improved optic nerve structure in a rat model of optic nerve compression. Originally announced in July and December 2024, the study has expanded to include a larger animal group[1].
Professor Rotenstreich declared, "We're excited to present the progress we've made in optic nerve regeneration at ARVO, where the future of vision science is being shaped. Our data sparked great interest among our peers and the broader scientific community, who are eager for real breakthroughs in this area."
Moving Forward: A Glaucoma Model
NurExone Biologic
Professor Michael Belkin, founder of the Goldschleger Eye Research Institute at Tel Aviv University and a member of NurExone's Scientific Advisory Board, weighed in, stating, "The results from ARVO suggest a clear potential for ExoPTEN to be used to treat optic nerve pathologies. We're now moving beyond the rat model and are probing an actual glaucoma model to explore the possibility of treating damaged optic nerves associated with this common disease."
Tradegate ·
A Potential Game Changer for Acute Glaucoma Treatment
According to NurExone's CEO, Dr. Lior Shaltiel, "We're breaking traditional assumptions in neurodegeneration the more we observe previously considered irreversible damaged neurons surviving and regaining function. Acute glaucoma poses a high risk for irreversible blindness and associated economic burden, costing healthcare systems billions annually. Even if we can preserve vision for a fraction of these cases, the potential clinical and economic benefits of ExoPTEN could be substantial."
Chart
Line chart with 52 data points.Chart für NurExone BiologicThe chart has 1 X axis displaying Time. Data ranges from 2024-05-13 14:00:00 to 2025-05-09 14:00:00.The chart has 1 Y axis displaying values. Data ranges from 0.332 to 0.535.Lade...End of interactive chart.
This therapy falls under NurExone's broader ExoTherapy platform, which also focuses on spinal cord and facial nerve regeneration. In preclinical spinal cord studies, ExoPTEN has demonstrated the ability to restore motor function in 75% of animals after complete transection[1]. As in the ophthalmological applications, the spinal cord and facial nerve programs utilize the same exosome-based product, signifying a potentially modular and scalable approach to restoring the nervous system.
The ARVO Annual Meeting: The Cradle of Vision Science Innovation
https://preventblindness.org/wp-content/uploads/2020/04/Economic-Burden-of-Vision-Final-Report_130611_0.pdf
Attending the ARVO Annual Meeting, the largest and most prestigious gathering in the vision research field, serves to validate the growing recognition of exosome-based strategies as a potential new frontier in regenerative medicine. The inclusion of NurExone in ARVO's scientific program emphasizes the immense promise for ExoPTEN and its potential role in revolutionizing optic nerve treatment.
https://money.tmx.com/quote/NRX/news/5642580836309330/ NurExone Advances Vision Restoration Strategy with Preclinical Data Presentation at the Association for Research in Vision and Ophthalmology ARVO 2025
For more information on NurExone, visit www.nurexone.com or follow the company on LinkedIn, Twitter, Facebook, and YouTube.
VISION INC.http://www.irw-press.com/alert_subscription.php?lang=en&isin=CA67059R1091
References
Nasdaq OTC ·
[1] NurExone Biologic Inc., "NurExone Advances Vision Restoration Strategy with Preclinical Data Presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2025," May 8, 2025, https://money.tmx.com/quote/NRX/news/5642580836309330/
Chart
Line chart with 0 data points.Chart für VISION INC.The chart has 1 X axis displaying Time. Data ranges from 2024-05-11 00:00:00 to 2025-05-12 00:00:00.The chart has 1 Y axis displaying values. Data ranges from 0 to 0.Lade...End of interactive chart.
[2] "Economic Burden of Vision," Prevent Blindness, April 2020, https://preventblindness.org/wp-content/uploads/2020/04/Economic-Burden-of-Vision-Final-Report_130611_0.pdf
Recent Releases:
- "Why a "Mar-a-Lago Accord" could destroy the dollar"
- "Defense stocks: After the recent rally, do they have more potential?"
- "Which cryptocurrency chart still offers promise?"
You might also like:
- "IRW-News: Dr. Reuter Investor Relations: Q4 Update and 2024 Annual Results: NurExone on a Growth Trajectory"
- "IRW-News: InnoCan Pharma Corporation: Innocan Pharma Receives Its First Patent in Mexico for Its Topical Pain Relief"
- "GNW-News: BioNTech Reports First Quarter 2025 Results and Business Update"
- "GNW-News: BioNTech Appoints Ramón Zapata as New Chief Financial Officer"
- "IRW-News: BioNxt Solutions Inc.: BioNxt Solutions Reports Extended Patent Protection from the Eurasian Patent Organization"
Stock Info:
- NurExone Biologic Inc. - Tradegate Chart
- VISION INC. - Nasdaq OTC Chart
- NurExone Biologic's exosome-based therapy, ExoPTEN, has shown promise in restoring retinal activity and improving optic nerve structure in a rat model of optic nerve compression.
- ExoPTEN, a part of NurExone Biologic's broader ExoTherapy platform, has the potential to treat not only optic nerve pathologies but also spinal cord and facial nerve regeneration.
- Research presented at the ARVO Annual Meeting, a significant gathering in the vision research field, highlights the immense promise of exosome-based strategies in regenerative medicine, particularly for optic nerve treatment.
- CBD, a neuroprotective compound, could potentially be used in combination with exosome-based therapies like ExoPTEN to treat neurological disorders, offering novel health-and-wellness therapies and treatments.
- The regulatory environment for such therapies and treatments is crucial, as successful FDA approvals could pave the way for the restoration of vision in various medical-conditions associated with optic nerve damage.
- In light of these advancements in vision restoration strategies, the medical-conditions and economic burden associated with acute glaucoma represent a significant opportunity for ExoPTEN to make a substantial impact, potentially preserving vision for a fraction of affected cases.
